• In late March 2026, Medtronic reported a series of U.S. FDA clearances and approvals across cardiac and surgical devices, including the AI-enabled Stealth AXiS surgical system for cranial and ENT procedures and an expanded indication for its OmniaSecure defibrillation lead, alongside a new U.S. distribution agreement for Merit Medical’s ViaVerte basivertebral nerve ablation system.
• Together, these moves highlight Medtronic’s push toward integrated, AI-supported platforms and broader therapy options in spine, neurosurgery, and cardiac care, potentially deepening its role in complex, procedure-driven medtech markets.
• We’ll now examine how the Stealth AXiS system’s AI-enabled, multi-specialty surgical platform could influence Medtronic’s existing investment narrative.

Uncover the next big thing with 33 elite penny stocks that balance risk and reward.

Medtronic Investment Narrative Recap

To own Medtronic, you need to believe that its scale in cardiovascular and procedure-driven medtech, combined with steady innovation in AI and robotics, can offset margin pressure and slower pockets like U.S. Diabetes. The latest clearances and distribution deal support that innovation story, but do not appear to materially change the key near term watchpoints around product mix, manufacturing execution, and progress on the Diabetes separation.

Among the recent announcements, the FDA clearance of the AI-enabled Stealth AXiS system for cranial and ENT procedures looks most connected to Medtronic’s push into integrated, higher value surgical platforms. If this multi specialty system gains traction alongside Hugo and other digital tools, it could help shift the portfolio toward more technology rich procedures, which is important for easing margin mix headwinds and supporting the broader investment case over time.

However, even with these promising launches, investors should be aware that continued gross margin pressure from product mix and ramp up challenges could still...

Medtronic's narrative projects $42.1 billion revenue and $6.5 billion earnings by 2029.

Uncover how Medtronic's forecasts yield a $111.31 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Ten Simply Wall St Community members currently see Medtronic’s fair value between US$91.87 and US$111.31, highlighting wide individual views. Against that backdrop, ongoing margin pressure from mix shifts and large product ramp ups remains a key issue for future performance that readers should assess from several angles.

Explore 10 other fair value estimates on Medtronic - why the stock might be worth as much as 28% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Medtronic research is our analysis highlighting 6 key rewards that could impact your investment decision.
• Our free Medtronic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medtronic's overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 26 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.